May 3, 2018 / 8:27 PM / 6 months ago

BRIEF-Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41

May 3 (Reuters) - Alnylam Pharmaceuticals Inc:

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

* Q1 NON-GAAP LOSS PER SHARE $1.22

* Q1 REVENUE VIEW $33.6 MILLION — THOMSON REUTERS I/B/E/S

* Q1 EARNINGS PER SHARE VIEW $-1.47 — THOMSON REUTERS I/B/E/S

* ALNYLAM PHARMACEUTICALS - REMAINS ON TRACK TO END 2018 WITH ABOUT $1.0 BILLION OF CASH, CASH EQUIVALENTS, AMONG OTHERS

* NOW EXPECTS ITS 2018 ANNUAL NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $420 MILLION TO $460 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below